Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

WVE-003

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: huntingtin (HTT) · developed by Wave Life Sciences

Phase 1/2 Most advanced trial (none active)
WVE Developer
1 Registered trials

What is WVE-003?

WVE-003 is an allele-selective stereopure antisense oligonucleotide designed to reduce huntingtin protein production. It is being studied in Huntington disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
huntingtin (HTT)
Mechanism
Gene silencing: huntingtin (HTT)
Therapy area
Neurology
Developer
Wave Life Sciences (WVE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05032196 Phase 1/2 Huntington Disease Completed WVE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Huntington Disease

Other drugs acting on HTT

ALN-HTT02 Phase 1 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2

More from Wave Life Sciences

WVE-004 Phase 1/2 WVE-006 Phase 1/2 WVE-007 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2 WVE-210201 Phase 2/3 WVE-N531 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.

Follow WVE, the company behind WVE-003

See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WVE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.